Skip Navigation



European Heart Journal Advance Access published online on November 7, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi637
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
27/3/357    most recent
ehi637v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rienstra, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rienstra, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2005; all rights reserved
Received April 13, 2005
Revised October 18, 2005
Accepted October 20, 2005

Clinical research

Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study

Michiel Rienstra 1, Isabelle C. Van Gelder 1*, Vincent E. Hagens 1, Nic J.G.M. Veeger 2, Dirk J. Van Veldhuisen 1, Harry J.G.M. Crijns 3, and for the RACE Investigators

1 Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
2 Trial Coordination Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
3 Department of Cardiology, University Hospital, Maastricht, The Netherlands

* To whom correspondence should be addressed.
Isabelle C. Van Gelder, E-mail: i.c.van.gelder{at}thorax.umcg.nl


  Abstract

Aims To compare outcome of AF patients with effective rhythm control with patients treated with rate control.

Methods and results Out of the 266 AF patients randomized to rhythm control in the RACE study, 49 patients turned to long-term sinus rhythm and were continuously treated with oral anticoagulation. The incidence of the primary endpoint in these patients was compared to that in 178 patients out of the initial 256 rate-control patients of RACE who were in AF and using oral anticoagulation continuously. Baseline characteristics of both groups were not different. After a mean follow-up of 2.3 ± 0.6 years, the primary endpoint (a composite of cardiovascular mortality, heart failure, thrombo-embolic complications (TECs), bleeding, serious adverse effects of antiarrhythmic drugs and pacemaker implants) was 22.4% in the rhythm-control group vs. 15.2% in the rate-control group. Multivariable regression analysis indicated coronary artery disease, heart failure, and digitalis as independent risk indicators of cardiovascular morbidity and mortality. Chronic sinus rhythm did not matter.

Conclusion Among patients who remained on warfarin, those who mostly were maintained in sinus rhythm under a rhythm-control strategy did not have a superior prognosis compared to those who remained in AF under a rate-control strategy.

Keywords: Atrial fibrillation; Rhythm control; Rate control; Morbidity; Mortality.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
L Friberg, N Hammar, N Edvardsson, and M Rosenqvist
The prognosis of patients with atrial fibrillation is improved when sinus rhythm is restored: report from the Stockholm Cohort of Atrial Fibrillation (SCAF)
Heart, June 15, 2009; 95(12): 1000 - 1005.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
C McKenna, S Palmer, M Rodgers, D Chambers, N Hawkins, S Golder, S Van Hout, C Pepper, D Todd, and N Woolacott
Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom
Heart, April 1, 2009; 95(7): 542 - 549.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
M. E.W. Hemels, J. H. Ruiter, G. P. Molhoek, N. J.G.M. Veeger, A. C.P. Wiesfeld, A. V. Ranchor, M. van Trigt, A. Pilmeyer, I. C. Van Gelder, and for The Features in AT500TM study; Chances for pat
Right atrial preventive and antitachycardia pacing for prevention of paroxysmal atrial fibrillation in patients without bradycardia: a randomized study
Europace, March 1, 2008; 10(3): 306 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
R. Nieuwlaat, L. W. Eurlings, A. Capucci, and H. J.G.M. Crijns
Atrial fibrillation in the 'real world': undecided issues
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I122 - I128.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
M. E.W. Hemels, A. C.P. Wiesfeld, D. J. Van Veldhuisen, M. P. Van den Berg, and I. C. Van Gelder
Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation in patients with systolic heart failure: a comparison with patients with normal left ventricular function
Europace, April 1, 2007; 9(4): 239 - 245.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
I. C. Van Gelder and M. E.W. Hemels
The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm
Europace, November 1, 2006; 8(11): 943 - 949.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.